Compare Amylx Pharmaceuticals Inc (AMLX) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Cintas Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Cintas Corporation trades at $180.27 (market cap $71.88B). The key difference: Cintas Corporation is far larger — about 36.3× Amylx Pharmaceuticals Inc's market cap, and Cintas Corporation pays a 1% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CTAS | |
|---|---|---|
Market Cap | $1.98B | $71.88B |
Sector | Health | Industrials |
52-Week High | $18.70 | $226.27 |
52-Week Low | $7.64 | $163.55 |
Enterprise Value | $1.70B | $74.62B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Cintas (CTAS) trades at $179.64, up 1.1% on the day, with a bullish technical signal and strong fundamentals including 17.57% net margin and consistent revenue growth to $10.34B in 2025. The stock shows robust cash flow from operations at $2.17B and has beaten earnings estimates in recent quarters. Recent news highlights upcoming Q4 2026 earnings and recognition as a top workplace, supporting positive sentiment.
Outlook remains favorable with a consensus price target of $212.50, though high valuation multiples (P/E 37.9) and competitive pressures pose risks. Earnings growth and market share expansion are key catalysts, but investors should monitor debt levels and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
